Livforsakringsbolaget Skandia Omsesidigt Acquires 568 Shares of Amgen Inc. (NASDAQ:AMGN)

Livforsakringsbolaget Skandia Omsesidigt grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,764 shares of the medical research company’s stock after purchasing an additional 568 shares during the quarter. Amgen comprises about 1.0% of Livforsakringsbolaget Skandia Omsesidigt’s investment portfolio, making the stock its 17th biggest position. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Amgen were worth $10,013,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. OFI Invest Asset Management bought a new position in Amgen in the 3rd quarter worth $26,000. Briaud Financial Planning Inc bought a new position in Amgen in the 3rd quarter worth $26,000. Strategic Investment Solutions Inc. IL bought a new position in Amgen in the 1st quarter worth $28,000. BOK Financial Private Wealth Inc. bought a new position in Amgen in the 4th quarter worth $29,000. Finally, Providence Capital Advisors LLC bought a new position in Amgen in the 3rd quarter worth $30,000. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of several research analyst reports. Raymond James initiated coverage on shares of Amgen in a research report on Thursday, March 28th. They issued a “market perform” rating on the stock. Truist Financial restated a “buy” rating and issued a $320.00 price target on shares of Amgen in a research report on Friday, April 12th. BMO Capital Markets upgraded shares of Amgen from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $286.00 to $326.00 in a research report on Tuesday, December 19th. StockNews.com lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Finally, SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $324.00 to $318.00 in a research report on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus price target of $298.38.

Amgen Stock Down 0.6 %

Shares of Amgen stock traded down $1.57 on Wednesday, hitting $264.07. The company had a trading volume of 2,174,839 shares, compared to its average volume of 2,862,361. The firm has a market capitalization of $141.52 billion, a P/E ratio of 21.25, a P/E/G ratio of 2.47 and a beta of 0.58. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The stock has a 50-day moving average of $278.62 and a 200-day moving average of $281.49.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. During the same quarter in the prior year, the company posted $4.09 earnings per share. The firm’s revenue was up 19.8% on a year-over-year basis. Research analysts predict that Amgen Inc. will post 19.47 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is currently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.